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INTRODUCTION 
 
Brown tumors are fibrovascular, expansile, lytic lesions that represent a tertiary manifestation of 
hyperparathyroidism.1  With primary hyperparathyroidism, the autonomous release of 
parathyroid hormone (PTH) from a neoplastic, hyperplastic, or ectopic parathyroid nodule 
stimulates pathologic resorption of bone by osteoclasts leading to elevated serum calcium. On 
the other hand, secondary hyperparathyroidism occurs when chronically low serum calcium 
levels, for instance with calcium wasting in the setting of end-stage renal disease (ESRD), 
triggers a physiologically analogous elevation in PTH release with subsequent bone resorption 
in the attempt to restore serum calcium levels. The result of both primary and secondary 
hyperparathyroidism can be excessive bone resorption2,3 which may terminate with the 
formation of brown tumors.4,5 
 
Though the incidence of brown tumors as a consequence of hyperparathyroidism is rare, 
ranging between 1.5% to 3%3,6, most of the existing literature details the occurrence of these 
lesions in the facial, thoracic, pelvic, and spinal skeleton.4,5 Reports regarding involvement of 
the skull base, specifically the sellar and parasellar region, have remained exceedingly rare.3 
The varied clinico-diagnostic profiles reported in the already scarce literature preclude a well-
founded consensus on the proper description, diagnostic workup, and/or management of these 
lesions. In this study, we report a patient with a histologically confirmed brown tumor in the clival 
region and provide a systematic review of past literature to evaluate clinical, diagnostic, and 
management trends. 
 
METHODS 
 
Case Report 
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A 51-year-old male presented to the Emergency Department (ED) complaining of a few weeks 
of neck pain. The patient’s medical history was notable for ESRD for which he had been 
receiving dialysis for 4.5 years. Review of systems was remarkable for dysphagia and a 
sensation of fullness in the tongue. Physical exam revealed left tongue atrophy and mild 
diplopia. His visit to the ED was complicated by hyperkalemia due to a missed dialysis regimen, 
and he consequently suffered pulseless cardiac arrest from which he was successfully 
resuscitated. During his subsequent workup, laboratory testing revealed an elevated PTH of 
1,385 pg/mL (normal range: 10 - 65) in the setting of normal serum calcium of 9.1 mg/dL 
(normal range: 8.4-10.2). At this juncture, a maxillofacial computed tomography (CT) scan 
without contrast was obtained and showed a lytic, expansile, and hyperdense mass involving 
the left clivus (Figure 1a-b). Magnetic resonance imaging (MRI) of the head with contrast 
showed a 4.2 cm by 1.5 cm enhancing mass of the left inferior clivus (Figure 1c). 
 
A trans-nasal endoscopic approach was employed to resect the clival tumor. Histopathologic 
examination demonstrated multinucleated giant cells proliferating in a background of 
fibrovascular stroma with reactive bone formation (Figure 2a-c). 
 
Following resection of the clival tumor, the patient was further evaluated for secondary 
hyperparathyroidism. Post-operative lab testing revealed normocalcemia in the setting of a 
persistently elevated PTH of 1,607pg/mL and a single-photon emission computed tomography 
(SPECT) scan revealed parathyroid hyperplasia. The patient received a total parathyroidectomy 
for definitive surgical management of his secondary hyperparathyroidism. Post-operative PTH 
testing confirmed reversal of hyperparathyroidism. The patient was discharged on post-
operative day 1 on an appropriate calcium supplementation regimen. At his 1-month post-
operative follow up, the patient reported complete resolution of his symptoms. 
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Systematic Review 
 
We aimed to identify all full-text, peer-reviewed reports pertaining to brown tumors of the 
sellar/parasellar region. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) reporting standard7 served as a guideline for our review. 
Eligibility criteria for inclusion and exclusion were determined prior to the literature search. 
Studies were included if they: (1) reported on sellar/parasellar brown tumors, (2) included key 
patient demographics and history findings, (3) provided key diagnostic findings including 
laboratory and imaging findings, (4) reported treatment modalities as well as follow-up data. 
Studies were excluded if they did not meet inclusion criteria and/or were: (1) a review of, or 
commentary on other pre-existing literature, (2) an editorial, (3) not written in English. Included 
articles were reviewed by two authors (M.A. and O.N.). On December 1, 2018, a thorough and 
comprehensive search of the PubMed, Ovid MEDLINE, Scopus, and Google Scholar databases 
was conducted to identify eligible studies. The search terms used included “brown tumors”, 
“sellar brown tumor”, “parasellar brown tumor”, and “clival brown tumor”. 
 
The following information, when available, was extracted from the included reports: author, year 
of publication, patient demographics, character and duration of symptoms, abnormal lab values, 
imaging characteristics, histopathologic descriptions, management modalities, and follow-up 
data. 
 
RESULTS 
 
Study Selection 
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A summary of the PRISMA protocol is provided in Figure 3. A systematic search of PubMed, 
MEDLINE, Scopus, and Google Scholar databases yielded a total of 118 articles. Thirty-two 
(32) duplicate articles were removed leaving 86 articles eligible for preliminary title and abstract 
screening. After screening, 56 articles did not meet inclusion criteria and were thus excluded. 
The remaining 30 articles were subjected to a comprehensive full-text review. Subsequently, 
only 7 articles were eligible for final inclusion in the systematic review3,6,8–12. All frequency 
results are based on a total of 8 sellar/parasellar brown tumor cases (7 previously documented 
cases in addition to the current case report). 
 
Demographics and Clinical Findings 
The publication dates ranged from 1986 – 2014. A summary of the demographic and clinical 
profile of each reported case is provided in Table 1. All reported cases involved female patients, 
with the current reported case emerging as the only documented case of a sellar/parasellar 
brown tumor in a male patient. Patient age ranged from 18 to 59 years with a mean of 42.75 
years. Five of eight cases provided a past medical history (62.5%), four of which were notable 
for ESRD (80%). Reported symptoms included visual disturbances such as decreased visual 
acuity or diplopia (n=6), headache (n=5), fatigue (n=3), nausea/vomiting (n=2), chest pain (n=1), 
neck pain (n=1), and dysphagia (n=1). Duration of symptoms ranged from 1 day to 24 months 
with a mean of 4.14 months. All reports provided a description of laboratory values. Laboratory 
findings included elevated alkaline phosphatase (ALP) (n=7), elevated PTH (n=6), 
hypercalcemia (n=5), azotemia (n=3), hypophosphatemia (n=2), hypocalcemia (n=2), anemia 
(n=2), hyperphosphatemia (n=1), and hyperchloremia (n=1). A summary of lab findings is also 
provided in Table 1. 
 
Imaging and Histopathologic Findings 
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Reported preoperative imaging modalities included maxillofacial CT (n=6) and MRI head/neck 
(n=6), and skull radiographs (n=2). In all 6 cases where CT findings were provided, the 
sellar/parasellar lesions were noted to be expansile and lytic. Contrast enhancement was noted 
on 5 MRIs (83.3%) and hyperintensity was reported on T2-weighted (T2W) imaging in 4 MRIs 
(66.7%). Imaging modalities employed in concurrent workup of hyperparathyroidism included 
parathyroid ultrasound (n=2), parathyroid scintigraphy (n=2), MRI of the neck (n=2), bone 
scintigraphy (n=1), and SPECT scan (n=1). Histopathologic findings were reported in 7 of the 
reports (87.5%). Similar histology of multinucleated giant cells surrounded loose fibrovascular 
stroma was noted in all of these cases (as demonstrated in Figure 2). All imaging and 
histopathologic findings are detailed in Table 2. 
 
Tumor Characteristics, Management, and Follow-Up Status 
Tumor characteristics (location and size) are summarized in Table 1. All 8 reports documented 
the location of the brown tumor. Tumor locations reported included the sphenoid bone (n=7), 
occipital bone (n=2), parietal bone (n=1), and clivus (n=1). Two cases reported involvement of 
anatomic sites in addition to the skull base i.e. cervical spine and multiple lytic rib lesions, 
respectively. Tumor size was reported in 4 of the 8 case reports (50%) with a mean size of 3.1 x 
3.0 x 2.5 cm. 
 
Surgical management was reported in all 8 cases. Extirpation of the sellar/parasellar lesion was 
documented in 4 of the 8 cases (50%). A trans-nasal approach was employed in all 4 cases. 
The remainder received only endocrine surgery for management of hyperparathyroidism. 
Management information is summarized in Table 1. 
 
Length of follow-up was documented in six of eight cases (75%) with a mean follow-up time of 
1.3 years and a range of 0.5 to 3 years. All patients who received trans-nasal resection of their 
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sellar/parasellar lesions exhibited complete or significant symptom resolution. Symptom 
recurrence was noted in 1 case reported by Schweitzer et al.9 Surgical complications related to 
endocrine surgery were noted in 2 cases11,12, whereby patients experienced persistent 
hypocalcemia following parathyroidectomy. Both patients were successfully treated with calcium 
and vitamin D supplementation. No surgical complications from trans-nasal resections were 
reported.  
 
DISCUSSION 
Brown tumors are osteolytic, expansile lesions resulting from hyperparathyroidism that 
represent a tertiary fibro-osseous remodeling reaction rather than a true neoplasm.6 Excess 
PTH in hyperparathyroidism drives osteoclastic and osteoblastic processes that subsequently 
cause bony resorption and fibro-osseous remodeling of the cortex and marrow.8 Although these 
lesions were first described by Gerhard Engle in 186413, their association with 
hyperparathyroidism was reported later in 1905 by Askanazy.3 However, this relation between 
brown tumors and hyperparathyroidism has been infrequently reported after the advent of 
biochemical testing for hypercalcemia and hyperparathyroidism. Since such testing has allowed 
for early detection and management of hyperparathyroidism, and given that brown tumors 
progress slowly and manifest late in the natural history of hyperparathyroidism, the overall 
incidence has decreased secondary to early intervention for hyperparathyroidism.11 
 
Studies have found that the incidence of brown tumors is higher in primary hyperparathyroidism 
(usually caused by parathyroid adenomas or hyperplasia) at 3% to 5%, than in secondary 
hyperparathyroidism (usually caused by chronic renal failure or vitamin D deficiency) at 1.5% to 
1.7%.3,6 As was the case with the patient presented in our study, the authors agree with the 
hypothesis put forward by Kanaan et al suggesting that perhaps an increase in incidence of 
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brown tumors from secondary hyperparathyroidism may now be observed given the increased 
longevity of patients with ESRD due to improved dialysis technology and services.3  
 
Brown tumors primarily occur in the mandible, clavicle, ribs, pelvis, and long bones such as the 
femur.6,12 Although studies have reported involvement of the maxilla, palate, temporal bone, 
nasal cavity, and orbital bone in the craniofacial region, reports of sellar/parasellar brown tumors 
remain exceedingly rare.6 Interestingly, and as demonstrated by our results, these limited 
reports of sellar/parasellar brown tumors show a tendency to occur in females (n=7, 87.5%), 
perhaps due to the higher incidence of hyperparathyroidism in females as compared to 
males.14,15 
 
The clinical presentation of brown tumors varies depending on the anatomical site of the lesion. 
Sellar/parasellar brown tumors most commonly present with headaches and/or visual changes, 
but other symptoms including nausea, vomiting, and focal neurological deficits have been 
reported.3,6,8–12 Histologically, brown tumors consist of multinucleated osteoclast-like giant cells 
in a spindle cell connective tissue stromal background. Large areas of bone resorption, 
hemorrhagic foci, and multifocal hemosiderin deposits represent degenerative changes that 
commonly occur in brown tumors.6,8,12 Accumulation of hemosiderin imparts a reddish-brown tint 
to the lesions, giving the lesions their name (i.e. brown tumors).3 
 
Key differential diagnoses for sellar/parasellar lesions often include invasive pituitary tumors, 
fibrous dysplasia, carcinomas, chordomas, chondrosarcomas, and neuroendocrine tumors.3,16 
The rarity of sellar/parasellar brown tumors generates a significant potential for misdiagnosis. 
Even at a histological level, the presence of giant cells necessitates a great deal of diagnostic 
astuteness to differentiate brown tumors of hyperparathyroidism from giant-cell reparative 
granulomas and true giant-cell tumors.6  
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Although the appearance of sellar/parasellar brown tumors on radiographs has not been 
classified, brown tumors in other anatomic areas classically exhibit widespread subperiosteal 
bone resorption.10 This is consistent with the case reported by Erem et al that documented 
diffuse osteopenia with salt-and-pepper stippling seen on skull x-ray.8 Radiographic findings 
were also reported by Takeshita et al where opacification of the sphenoid sinus was noted.6 On 
CT imaging, sellar/parasellar brown tumors appear as lytic, expansile, and enhancing lesions, 
similar to brown tumors occurring in other regions of the body. The lytic and expansile nature of 
these lesions suggests a slow-growing process.6 Although varying MR imaging characteristics 
have been reported for sellar/parasellar brown tumors, our review revealed a trend where by 
these tumors were often hyperintense on T2W and enhanced with contrast.6,8,10,12 Heterogeneity 
was often reported on T2W images given the heterogenous pathological background these 
lesions consisting of hemorrhagic foci, hemosiderin deposits, and other cystic components.  
 
The exceedingly rare nature of sellar/parasellar brown tumors has precluded the establishment 
of definitive therapeutic guidelines. Previous studies have advocated that the first step in 
management is to treat (either medically or surgically) the primary underlying endocrine etiology 
with the ultimate goal of achieving normalized lab values with ensuing spontaneous regression 
of brown tumors. However, the regression response with this strategy in sellar/parasellar lesion 
remains unclear, with reports showing minimal response12 or even progression.9 Therefore, in 
cases of larger brown tumors that are persistent and unresponsive to endocrine therapy, or in 
cases where acute deficits are present and lasting complications are possible, acute surgical 
decompression is indicated and favored. Our review of literature demonstrates that surgical 
extirpation yields favorable outcomes with complete symptom resolution noted in all patients 
who received surgical excision. 
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CONCLUSION 
Sellar/parasellar brown tumors are a rare, tertiary manifestation of a common disease entity (i.e. 
hyperparathyroidism), and therefore can be elusive to diagnose. Appropriate, timely diagnosis 
(and consequent management) often requires a high index of clinical suspicion augmented by a 
complete workup including biochemical testing, imaging, and histopathologic analysis. Surgical 
removal of the skull base lesion is favored in the event that the lesion is causing compressive 
symptoms, or if it is unresponsive to management of hyperparathyroidism. 
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FIGURE LEGENDS 
 
Figure 1A: Axial maxillofacial CT without contrast demonstrating left clival brown tumor (arrow) 
 
Figure 1B: Sagittal maxillofacial CT without contrast demonstrating clival brown tumor (arrow)  
 
Figure 1C: Axial, T1-weighted, post-contrast MRI showing an enhancing left clival mass (arrow)  
 
Figure 2. H&E-stained sections reveal focally preserved osteoid and large areas of bone 
resorption (A, 100x, measuring bar = 100 µm) characterized by multinucleated osteoclast-like 
giant cells and fibroblasts (B, 400x, measuring bar = 50 µm). Multifocal hemosiderin depositions 
(C, 400x, measuring bar = 50 µm) represent degenerative changes that commonly occur in 
brown tumors.   
 
Figure 3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram of article identification and selection. 
Table 1. Summary of patient information, medical and surgical management, and follow-up status. 
Study Age/Sex Symptoms (Duration) Abnormal lab values Primary 
disturbance 
Tumor 
location 
Tumor size 
(cm) 
Medical 
management 
Surgical Management Follow-up (Duration) 
Schweitzer et 
al. 1986 
46/F Left frontal & retro-
orbital headaches (6mo);  
Left diplopia and vision 
loss (1mo) 
Hypercalcemia,  
elevated ALP 
1º HPT due to 
parathyroid 
adenoma 
Sphenoid 
sinus 
NA None Resection of parathyroid 
adenoma following 
endoscopic and open 
biopsies of sellar lesion. 
Despite normocalcemia, 
patient reported new-onset 
disequilibrium, tinnitus, and 
hearing loss in left ear. 
CT and histopathology 
revealed progression of BT 
(16mo) 
Kanaan et al. 
1998 
21/F Headache, nausea, 
vision impairment (4mo) 
Hypocalcemia, 
hypochloremia, 
hyperphosphatemia, 
elevated ALP 
2º HPT due to 
ESRD 
Sphenoid 
sinus 
NA None TNR of sellar lesion (1 
month after decompression 
of lesion through a right 
lateral rhinotomy and 
external ethmoidectomy) 
Minor post-op changes seen 
on MRI with dramatically 
improved vision (36mo) 
Erem et al. 
2004 
47/F Headache, dizziness, 
diffuse arthralgia & 
fatigue (24mo); 
Nausea & vomiting 
(6mo) 
Anemia, 
elevated BUN & Cr, 
hypercalcemia, elevated ALP, 
elevated iPTH 
1º HPT due to 
parathyroid 
adenoma 
 
Sphenoid 
sinus and 
occipital 
bone 
Sphenoid:  
5 x 3.5 x 3.5cm 
 
Occipital:  
3 x 2 x 2cm 
None Resection of right-inferior 
parathyroid adenoma 
Complete symptom resolution 
with normalized labs except an 
elevated ALP (12mo)  
Takeshita et al. 
2004 
47/F Headache, left ptosis, 
and worsening right 
diplopia (3 days) 
Elevated BUN and Cr, 
hypocalcemia,  
elevated ALP, elevated iPTH 
2º HPT due to 
ESRD 
 
Sphenoid 
sinus 
NA None TNR of sellar lesion Dramatic symptom relief (NA)  
Yilmazlar et al. 
2004 
59/F Headache, impaired 
vision in the right eye, 
and diplopia (5mo); 
Reduced vision and 
ptosis in left eye (1mo) 
Hypercalcemia, 
hypophosphatemia, elevated 
ALP, elevated PTH 
1º HPT due to 
parathyroid 
adenoma 
 
Sphenoid 
sinus and 
parietal 
bone 
Parietal: 
1 x 2cm 
 
Sphenoid:  
NA 
None TNR of sellar lesion Improved vision with 
normalized labs (8mo) 
Lando HM 2012 18/F Chest pain (NA) Hypercalcemia, elevated 
ALP, elevated PTH 
1º HPT due to 
parathyroid 
adenoma 
Sphenoid 
sinus 
3.4 x 4.7cm None Resection of parathyroid 
adenoma 
Marginal regression of 
sphenoidal lesion to 3 x 4cm 
(18mo) 
Loya-Solis et al. 
2014 
53/F Bitemporal hemianopsia 
and diplopia, fatigue, 
generalized weakness, 
and somnolence (2mo) 
Anemia, hypercalcemia, 
hypophosphatemia, 
hypomagnesemia, elevated 
ALP, elevated PTH 
1º HPT due to 
parathyroid 
carcinoma 
 
Sphenoid 
sinus 
3 x 3 x 2cm Hydration, 
furosemide, 
zoledronate 
Left hemithyroidectomy & 
ipsilateral 
parathyroidectomy 
Improved visual fields with 
normalized labs(6mo) 
Present case, 
2018 
51/M Neck pain, dysphagia, 
and sensation of fullness 
of tongue, 1 month 
Elevated PTH 2º HPT due to 
ESRD 
 
Left clivus & 
occipital 
condyle 
2.9 x 1.6cm None TNR of clival lesion followed 
by total parathyroidectomy 
with auto-transplantation 
Complete symptom resolution, 
with normalized labs (6mo) 
ALP, alkaline phosphatase; BT, brown tumor; BUN, blood urea nitrogen; Cr, creatinine; ESRD, end-stage renal disease; F, female; HPT, hyperparathyroidism; iPTH, intact parathyroid hormone; NA, not 
available; PTH, parathyroid hormone; TNR, trans-nasal resection 
 Table 2. Summary of imaging, gross, and histopathologic findings. 
Study XR CT MRI Histopathology Parathyroid imaging 
Schweitzer et 
al. 1986 
NA Expansile, lytic heterogenous 
sellar mass with remodeling of 
surrounding bone and 
involvement of cavernous sinus 
NA Diffuse fibrosis with mixed chronic 
inflammatory infiltrate 
NA 
Kanaan et al. 
1998 
NA Expansile, lytic sellar mass with 
remodeling of surrounding bone 
and involvement of right orbit 
and posterior ethmoid sinus 
Lesion morphology same as CT 
T1: Heterogenous hyperintense foci 
T2: Heterogenous hyperintense foci 
Regenerative bone surrounded by 
fibrovascular stroma and 
multinucleated giant cells 
NA 
Erem et al. 
2004 
Diffuse osteopenia 
and subperiosteal 
resorption, salt-and-
pepper stippling in the 
skull 
NA Expansile, lytic sellar mass eroding into 
medial wall of right orbit and posterior 
ethmoid sinus 
T1: Contrast enhancing 
T2: Hyperintense 
Multinucleated giant cells 
surrounded by fibrovascular 
stroma with focal hemorrhages 
and hemosiderin-laden 
macrophages as well as focal sites 
of reactive woven bone formation 
Parathyroid U/S revealed a 26 x 18mm heterogenous mass 
at posterior-inferior right thyroid lobe 
MRI of neck showed hyperintensity in the same area 
Histopathologic examination of resected mass revealed 
parathyroid adenoma 
Takeshita et 
al. 2004 
Opacification of the 
sphenoid sinus 
Expansile, lytic heterogenous 
sellar mass with remodeling of 
surrounding bone 
Lesion morphology same as CT 
T1: Isointense, contrast enhancing  
T2: Heterogeneously hyperintense 
Multinucleated giant cells, loose 
fibrous stroma with spindle-shaped 
mononucleated cells, focal 
hemorrhage and hemosiderin 
deposition 
NA 
Yilmazlar et al. 
2004 
NA Expansile, lytic sellar mass with 
remodeling of surrounding bone 
and involvement of posterior 
ethmoid sinus; 
Distinct lytic lesion in noted in 
right parietal bone 
Lesion morphology same as CT 
T1: Isointense, contrast enhancing 
T2: Hyperintense, contrast enhancing 
Central osteoclasts with focal areas 
of fibroblasts and hemorrhage 
MRI of neck revealed a T1 hypointense, T2 hyperintense left 
inferior parathyroid lesion; 
Parathyroid scintigraphy revealed an adenoma in the same 
area; 
Bone scintigraphy displayed increased activity in proximal 
right radius, parietooccipital area, and left tibia 
Lando HM 
2012 
NA NA Sellar mass with involvement of optic 
chiasm and cavernous sinus 
T1: NA 
T2: “Markedly dark”, contrast enhancing 
 NA Parathyroid U/S revealed a heterogenous parathyroid mass; 
Histopathologic examination revealed parathyroid adenoma 
Loya-Solis et 
al. 2014 
NA Expansile, lytic heterogenous 
sellar mass with remodeling of 
surrounding bone and erosion 
the sphenoid corpus 
NA Multinucleated giant cells in 
fibrous stroma with hemosiderin 
deposition 
Parathyroid U/S and scintigraphy revealed enlarged right 
inferior parathyroid gland and hyperfunction; 
Histopathologic examination of resected parathyroid gland 
was diagnostic of parathyroid carcinoma 
Present case, 
2018 
None Expansile, lytic heterogenous 
sellar mass with remodeling of 
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A 
Figure 1A: Axial maxillofacial CT without contrast demonstrating left clival brown tumor (arrow) 
 
 
B 
Figure 1B: Sagittal maxillofacial CT without contrast demonstrating clival brown tumor (arrow) 
 
 
C 
Figure 1C: Axial, T1-weighted, post-contrast MRI showing an enhancing left clival mass (arrow) 
 
A 
B 
C 
Figure 2. H&E-stained sections reveal focally preserved osteoid and large areas of bone resorption (A, 
100x, measuring bar = 100 µm) characterized by multinucleated osteoclast-like giant cells and fibroblasts 
(B, 400x, measuring bar = 50 µm). Multifocal hemosiderin depositions (C, 400x, measuring bar = 50 µm) 
represent degenerative changes that commonly occur in brown tumors.   
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Figure 3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 
of article identification and selection.  
 
ABBREVIATIONS 
ALP  - Alkaline Phosphatase 
CT  - Computed Tomography 
ED  - Emergency Department 
ESRD  - End Stage Renal Disease 
MRI  - Magnetic Resonance Imaging 
PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
PTH  - Parathyroid Hormone 
SPECT -  Single Photon Emission Computed Tomography  
 
